Source-grounded facts extracted from ATOSSA THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ATOSSA THERAPEUTICS, INC. reported financial results for the first quarter ended March 31, 2026.
“On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.”
ATOSSA THERAPEUTICS, INC. terminated Prior Agreement with Jefferies LLC (effective 2026-02-19).
“On February 19, 2026, the Company delivered written notice to Jefferies LLC indicating that it is terminating the Open Market Sale Agreement SM (the “Prior Agreement”) by and between the Company and Jefferies LLC, dated November 19, 2024, effective as of February 19, 2026.”
ATOSSA THERAPEUTICS, INC. entered into Sales Agreement with Rodman & Renshaw LLC valued at up to $50,000,000 (effective 2026-02-20).
“On February 20, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into the At the Market Offering Agreement, dated February 20, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time up to $50,000,000 of shares of the Company’s common stock”
ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“February 17, 2026, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on February 21, 2025, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Co”
ATOSSA THERAPEUTICS, INC.: Approved a 15:1 reverse stock split of common stock and filed an amendment to the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, effective February 2, 2026 (effective 2026-02-02).
“the Company filed an amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware (the “Amendment”).”
ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company’s initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was inf”
Heather Rees was appointed as Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
“On June 27, 2024, the Board of Directors (the “Board”) of the Company appointed Heather Rees, previously the Company’s Senior Vice President, Finance and Accounting, to serve as Chief Financial Officer and to continue serving as principal financial and accounting officer, effective immediately.”
ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2024.
“On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update.”
ATOSSA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023”
ATOSSA THERAPEUTICS, INC. reported financial results for the year ended December 31, 2023.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the forth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.